CRISPR is going to change a lot in the life science industry and is perceived as THE discovery of the 21st century. Within the past 6 months, 3 companies went public, raising between €50M and €100M each (with valuation close to the billion), to bring about the CRISPR revolution. But the problem is, there is absolutely no clinical data yet to back any investment. Does this make it a blind gamble?
I had a great chat about the topic with a certain someone from one of the top 10 VCs in Europe during BIO-Europe. Though he had the opportunity to invest in one of the CRISPR companies, he refused and has some good arguments for skepticism of the new technology.
